IMPAKT 2013 Press Release: Study confirms Everolimus can overcome Trastuzumab resistance in IN HER-2 positive early breast cancer
Lugano-CH, Brussels-BE, 2 May 2013
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.
Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, ‘translational’ breast cancer research that is beginning to have an impact for patients.
“As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents,” Prof Campone said. “One of the objectives of this study was to determine molecular biomarkers that predict whether a patient’s cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone.”
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.
In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.
“Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction,” Prof Campone explains. “Therefore, using everolimus to inhibit mTOR, a major downstream effector of this pathway, can restore sensitivity to trastuzumab. In a pre-clinical model, everolimus also reverses trastuzumab resistance caused by upregulation of IGF-1R expression, an alternative signaling pathway, allowing IGF-1 to drive cell growth and proliferation.”
At the IMPAKT meeting, Prof Campone’s group report the first results of a clinical study and analysis of seven biomarkers in patients with early HER2-overexpressing cancers who were receiving treatment with trastuzumab alone, or everolimus plus trastuzumab.
Among the 80 patients (40 per arm), the clinical response rate was 35% in the trastuzumab arm and 45% in the patients who received both drugs. On the other hand, the pathological response rate was 43.5% among patients in the monotherapy arm, and 47.5% in the combination arm of the study.
“The conclusion of this paper in clinical practice is that the addition of everolimus to trastuzumab seems to improve the clinical response rate but not the pathologic response,” Prof Campone said.
The researchers also studied a group of seven molecular markers to explore whether they could be used to predict which patients would respond to the combination of everolimus and trastuzumab. The biomarkers were p4EBP1, pS6, eIF4E, Ki67, pAKT, LKB1, and caspase 3, all of which are involved in pathways that lead to the activation of mTOR.
“None of these biomarkers was able to predict which patients would see the benefit of the two drugs,” Prof Campone said. “It appears the combination of everolimus and trastuzumab is effective independently of the activation of the PI3K/AKT/mTOR pathway and without any anti-proliferative and pro-apoptotic effect.”
The study provides important confirmation of the benefit of adding everolimus in this clinical setting, comments Prof Christoph Zielinski, Chairman of the Department of Medicine I at Medical University Vienna, Austria.
“This is a rather small trial with a limited number of patients, although it quite unequivocally shows that the addition of everolimus to trastuzumab leads to an increase in clinical responses in Her-2/neu overexpressing breast cancer, as compared to trastuzumab alone,” he said.
“Thus, it not only adds to clinical possibilities which can be offered to patients, but also further explains the modalities of molecularly directed therapeutic manipulation in breast cancer,” said Prof Zielinski. However, the limited pathologic response constitutes a clear drawback from clinical observations.
"Nevertheless this study contributes to our assumptions on the application of molecularly targeted therapies in breast cancer in particular and in malignancies in general. It also helps to move to an era where the targeting of multiple molecular structures (like here with trastuzumab and everolimus) leads to ameliorated results by ‘hitting’ multiple growth-regulating mechanisms, but also avoiding treatment resistance which continues to be a major challenge in cancer treatment."
Notes to Editors
Session info: PI3K/AKT/mTOR: Targets/trials and biomarkers. An horizon scan and debate
Friday, 3 May 2013, 09:00 AM – 10:25 AM (CEST). Place: Gold Hall
Please contact the IMPAKT Press Office at email@example.com to schedule remote interviews or for any inquiry.
PREDICTIVE VALUE OF AKT/MTOR PATHWAY IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS FOR RESPONSE TO PREOPERATIVE TRASTUZUMAB (T) VS TRASTUZUMAB + EVEROLIMUS (T+E) IN PATIENTS (PTS) WITH EARLY BREAST CANCER (BC) : UNICANCER RADHER TRIAL RESULTS
M. Campone1, T. Bachelot2, X. Paoletti3, J. Merlin4, S. Delaloge5, D. Loussouarn6, J. Bonneterre7, M. Jimenez8, M. Rios9, I. Treilleux10
1Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, St. Herblain/FRANCE, 2Department Of Medical Oncology, Centre Léon Bérard, LYON/FRANCE, 3Biostatistics Department / Inserm U900, Institut Curie, PARIS/FRANCE, 4Département De Biopathologie-unité De Biologie Des Tumeurs-ea 4421 Sigreto Université De Lorraine, Centre Alexis Vautrin, Vandoeuvre-les-Nancy/FRANCE, 5Department Of Medicine, Institut Gustave Roussy, Villejuif/FRANCE, 6Department Of Pathology, Hôpital G&R Laënnec, St. Herblain/FRANCE, 7Department Of Medical Oncology, Centre Oscar Lambret, Lille/FRANCE, 8R&d Unicancer, UNICANCER, PARIS/FRANCE, 9Department Of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-les-Nancy/FRANCE, 10Department Of Pathology And Biopathology, Centre Léon Bérard, LYON/FRANCE
Background: Encouraging results have been achieved when E was combined with T and chemotherapy in T-resistant HER2+ metastatic BC but the mechanism of how mTOR inhibitors reverse resistance to T remains largely unexplained. Our study aims at evaluating the efficacy of adding E to T as preoperative therapy for primary HER-2+ operable BC pts and to evaluate molecular response biomarkers. We report the first results of the clinical study and the analysis of IHC biomarkers p4EBP1, Ki67, pAKT, pS6, eIF4E.
Methods: Eligible pts with HER2+ primary BC (IHC 3+ or FISH/SISH+) amenable to surgery were randomized to receive T alone (loading dose 4 mg/kg, then 2 mg/kg/W), or T+E (10 mg/d) for a 6W pre-operative treatment. All pts had baseline needle biopsies, tissue collected at surgery and blood samples for biomarkers and pharmacokinetic analysis. Main end point was clinical Response Rate (cRR) and study was designed to detect an increase from 10% with T to 40 % with T+E in 120 pts.
Results: From 07/2008 to 02/2012, 82 pts were randomised, 80 pts were evaluable (40 per arm) and study was considered as completed. BC was classified as T0, T1, T2 and T3 in 5% (4/84), 44% (37/84), 49% (41/84), and 2% (2/84), respectively. Median tumor size was 25 mm (range 0-90). 52/80 (65%) were evaluable for cRR and 77/80 (96%) for pathological Response Rate (pRR) among which 65 (81%) were evaluable for predictive analysis of baseline biomarkers. Efficacy results are reported in the table below:
|response||T arm||T+E arm|
|cRR||9/40 (22.5%)||14/40 (35%)|
|cCR||5/40 (12.5%)||8/40 (20%)|
|pRR (T-A+T-B)*||17/38 (45%)||19/39 (49%)|
|pCR(T-A)*||6/38 (16%)||3/39 (8%)|
* Sataloff's classification The most common grade 3-4 adverse effect with T+E was stomatitis in 17% of pts. E dose was reduced in 17% and permanently discontinued in 15% of pts. No cardiac event was reported. pCR was observed in 3 pts with measured biomarkers and was associated with high Ki67 and pAKT IHC staining intensity. No relation was observed between p4EBP1, pS6, eIF4E and pCR or pRR.
Conclusions: E+T improved the cRR comparing to T alone. No response predictive IHC biomarker was identified, warranting further investigations on biological samples. Pre and post-treatment variation of caspase 3 and Ki67 will be presented.
Keywords: trastuzumab, predictive biomarkers, pre-operative chemotherapy, mTOR inhibitor
Disclaimer: Information contained in this press release was provided by the abstracts’ authors and reflects the content of the studies. It does not necessarily express ESMO's or BIG’s point of view.
Thank you for rating!
You have already rated this page, you can only rate it once!